Strategies for discovering novel pancreatic cancer biomarkers.

[1]  E. Diamandis,et al.  Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9 , 2013, BMC Cancer.

[2]  Maria P. Pavlou,et al.  The long journey of cancer biomarkers from the bench to the clinic. , 2013, Clinical chemistry.

[3]  C. Borrebaeck,et al.  Identification of serum biomarker signatures associated with pancreatic cancer. , 2012, Cancer research.

[4]  N. Merchant,et al.  Serum HSP70: A Novel Biomarker for Early Detection of Pancreatic Cancer , 2012, Pancreas.

[5]  Qiu-ping Xie,et al.  DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[6]  E. Diamandis,et al.  Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery , 2012, BMC Medicine.

[7]  Qiwen Ben,et al.  DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. , 2012, Carcinogenesis.

[8]  N. D. Merrett,et al.  The prognostic and predictive value of serum CA19.9 in pancreatic cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[10]  M. Haider,et al.  Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience , 2012, Journal of Gastrointestinal Surgery.

[11]  E. Diamandis,et al.  Mining the malignant ascites proteome for pancreatic cancer biomarkers , 2011, Proteomics.

[12]  Yueguo Wang,et al.  Serum APRIL, a potential tumor marker in pancreatic cancer , 2011, Clinical chemistry and laboratory medicine.

[13]  C. Yeo,et al.  The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. , 2011, Advances in surgery.

[14]  C. Pilarsky,et al.  Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers , 2011, Molecular & Cellular Proteomics.

[15]  Wen-jun Zhang,et al.  Proteomic Analysis Identified DJ-1 as a Cisplatin Resistant Marker in Non-Small Cell Lung Cancer , 2011, International journal of molecular sciences.

[16]  T. Hwang,et al.  Secretome-Based Identification of ULBP2 as a Novel Serum Marker for Pancreatic Cancer Detection , 2011, PloS one.

[17]  W. Yao,et al.  Serum DJ‐1 as a diagnostic marker and prognostic factor for pancreatic cancer , 2011, Journal of digestive diseases.

[18]  William E Grizzle,et al.  Serum Biomarker Panels for the Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.

[19]  M. Goggins.  Markers of Pancreatic Cancer: Working Toward Early Detection , 2011, Clinical Cancer Research.

[20]  J. Habermann,et al.  Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview , 2011, Journal of Cancer Research and Clinical Oncology.

[21]  E. Collisson,et al.  Blinded by the Light: Molecular Imaging in Pancreatic Adenocarcinoma , 2010, Clinical Cancer Research.

[22]  M. Mino‐Kenudson,et al.  Plectin-1 as a Novel Biomarker for Pancreatic Cancer , 2010, Clinical Cancer Research.

[23]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[24]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[25]  E. Diamandis,et al.  Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.

[26]  Michael Goggins,et al.  Detection of Early-Stage Pancreatic Adenocarcinoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[27]  S. Hanash,et al.  The grand challenge to decipher the cancer proteome , 2010, Nature Reviews Cancer.

[28]  R. Andersson,et al.  Diabetes Mellitus in Pancreatic Cancer and the Need for Diagnosis of Asymptomatic Disease , 2010, Pancreatology.

[29]  Qiu-ping Xie,et al.  Novel Blood Biomarkers of Pancreatic Cancer–Associated Diabetes Mellitus Identified by Peripheral Blood–Based Gene Expression Profiles , 2010, The American Journal of Gastroenterology.

[30]  Maria P. Pavlou,et al.  Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.

[31]  M. Duffy,et al.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Hanlee P. Ji,et al.  Journal of Translational Medicine Identification of a Biomarker Panel Using a Multiplex Proximity Ligation Assay Improves Accuracy of Pancreatic Cancer Diagnosis , 2022 .

[33]  J. Winstanley,et al.  The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. , 2009, The American journal of pathology.

[34]  H. Friess,et al.  Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus , 2009, Cancer biology & therapy.

[35]  B. Mroczko,et al.  Clinical Significance of the Measurements of Serum Matrix Metalloproteinase-9 and Its Inhibitor (Tissue Inhibitor of Metalloproteinase-1) in Patients With Pancreatic Cancer: Metalloproteinase-9 as an Independent Prognostic Factor , 2009, Pancreas.

[36]  A. Basu,et al.  New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. , 2009, The Lancet. Oncology.

[37]  H. Wajant.  The role of TNF in cancer. , 2009, Results and problems in cell differentiation.

[38]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[39]  E. Diamandis,et al.  Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.

[40]  Huamin Wang,et al.  Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. , 2008, Cancer research.

[41]  Jinxiang Han,et al.  Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients , 2008, BMC Cancer.

[42]  Lin Chen,et al.  Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. , 2008, Oncology reports.

[43]  Michelle A. Anderson,et al.  A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.

[44]  C. Röcken,et al.  Proteomics of Pancreatic Cancer , 2008, Pancreas.

[45]  R. Hruban,et al.  PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma , 2007, Clinical Cancer Research.

[46]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[47]  N. Tsuji,et al.  Olfactomedin 4 promotes S‐phase transition in proliferation of pancreatic cancer cells , 2007, Cancer science.

[48]  W. Roberts,et al.  Performance characteristics of five automated CA 19-9 assays. , 2007, American journal of clinical pathology.

[49]  N. Duraker,et al.  CEA, CA 19‐9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice , 2007, Journal of surgical oncology.

[50]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Tatsuta,et al.  [Early detection of pancreatic cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[52]  Anneclaire J De Roos,et al.  Differences in Survival by Histologic Type of Pancreatic Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[53]  David Moher,et al.  The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration , 2003, Annals of Internal Medicine [serial online].

[54]  R. DePinho,et al.  Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.

[55]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[56]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[57]  T. Ørntoft,et al.  Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.

[58]  C. Haglund,et al.  The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. , 1994, British Journal of Cancer.

[59]  Kay Br,et al.  The impact of cancer biology, lead time bias, and length bias in the debate about cancer screening tests. , 1991 .

[60]  D. Witte,et al.  The impact of cancer biology, lead time bias, and length bias in the debate about cancer screening tests. , 1991, Journal of insurance medicine.

[61]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[62]  S. Kawa,et al.  Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. , 1987, Journal of the National Cancer Institute.

[63]  M. Tempero,et al.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.

[64]  C. Haglund,et al.  Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. , 1986, British Journal of Cancer.

[65]  M. Plebani,et al.  Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. , 1986, Bulletin du cancer.

[66]  F. Hanisch,et al.  Structure of tumor-associated carbohydrate antigen Ca 19-9 on human seminal-plasma glycoproteins from healthy donors. , 1984, European journal of biochemistry.

[67]  M. Herlyn,et al.  Specific antigen in serum of patients with colon carcinoma. , 1981, Science.

[68]  M. Herlyn,et al.  Colorectal carcinoma antigens detected by hybridoma antibodies , 1979, Somatic cell genetics.

[69]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.